Method for identifying and killing cancer cells
    1.
    发明授权
    Method for identifying and killing cancer cells 有权
    识别和杀死癌细胞的方法

    公开(公告)号:US07402307B2

    公开(公告)日:2008-07-22

    申请号:US10208243

    申请日:2002-07-30

    Abstract: The invention provides a method for activating a T lymphocyte by contacting the T lymphocyte with a dendritic cell (DC) that presents a telomerase reverse transcriptase (TRT) peptide in the context of an MHC class I or MHC class II molecule. The DC may be pulsed with a TRT polypeptide or may comprise a recombinant polynucleotide encoding a TRT such as hTRT. The invention also provides DCs comprising a recombinant TRT polynucleotide. The methods and compositions of the invention are used in prevention and treatment of cancers and other cell proliferation diseases or conditions.

    Abstract translation: 本发明提供了通过使T淋巴细胞与MHC I类或II类分子的上下文中呈现端粒酶逆转录酶(TRT)肽的树突状细胞(DC)接触来激活T淋巴细胞的方法。 DC可以用TRT多肽脉冲,或者可以包含编码TRT的重组多核苷酸,例如hTRT。 本发明还提供了包含重组TRT多核苷酸的DC。 本发明的方法和组合物用于预防和治疗癌症和其它细胞增殖疾病或病症。

    Intercellular adhesion mediators
    3.
    发明授权
    Intercellular adhesion mediators 失效
    细胞间黏附介质

    公开(公告)号:US5753631A

    公开(公告)日:1998-05-19

    申请号:US457886

    申请日:1995-05-31

    Abstract: The present invention is directed towards compositions and methods for reducing or controlling inflammation and for treating inflammatory disease processes and other pathological conditions mediated by intercellular adhesion. The compositions of the invention include compounds that selectively bind selectin receptors, the selectin binding activity being mediated by a carbohydrate moiety. The selectin-binding moieties of the invention are derivatives of a sialylated, fucosylated N-acetyllactosamine unit of the Lewis X antigen. Compounds containing a selectin-binding moiety in both monovalent and multivalent forms are included in the invention. The compounds of the invention are provided as pharmaceutical compositions which include, for example, liposomes that carry selectin-binding moieties of the invention. The invention further includes immunoglobulins capable of selectively binding an oligosaccharide ligand that is recognized by a selectin receptor.

    Abstract translation: 本发明涉及用于减少或控制炎症和治疗由细胞间粘附介导的炎性疾病过程和其它病理状况的组合物和方法。 本发明的组合物包括选择性结合选择素受体的选择素结合活性由碳水化合物部分介导的化合物。 本发明的选择素结合部分是Lewis X抗原的唾液酸化,岩藻糖化N-乙酰基乳糖胺单元的衍生物。 包含单价和多价形式的选择蛋白结合部分的化合物包括在本发明中。 本发明的化合物作为药物组合物提供,其包括例如携带本发明选择蛋白结合部分的脂质体。 本发明还包括能够选择性结合由选择素受体识别的寡糖配体的免疫球蛋白。

Patent Agency Ranking